Adynxx (ADYX) 10-Q 14 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	8-May-15
Document Information [Line Items]
Entity Registrant Name	Alliqua BioMedical, Inc.
Entity Central Index Key	1054274
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ALQA
Entity Common Stock, Shares Outstanding		24,397,062
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$10,939,194	$16,770,879
Accounts receivable	1,403,595	968,616
Inventory, net	1,601,727	1,411,748
Prepaid expenses and other current assets	814,278	477,824
Total current assets	14,758,794	19,629,067
Improvements and equipment, net	1,360,534	1,434,027
Intangible assets, net	4,154,624	4,387,293
Goodwill	4,100,295	4,100,295
Other assets	173,042	173,042
Total assets	24,547,289	29,723,724
Current Liabilities:
Accounts payable	1,802,498	1,757,742
Accrued expenses and other current liabilities	2,330,876	2,067,859
Warrant liability	292,181	304,223
Total current liabilities	4,425,555	4,129,824
Contingent consideration	3,039,134	2,931,598
Deferred tax obligation	69,835	67,000
Other long-term liabilities	81,986	84,071
Total liabilities	7,616,510	7,212,493
Commitments and Contingencies
Stockholders' Equity
Preferred Stock, par value $0.001 per share, 1,000,000 shares authorized, no shares issued and outstanding	0	0
Common Stock, par value $0.001 per share, 45,714,286 shares authorized; 16,821,243 and 16,202,689 shares issued and outstanding as of March 31, 2015 and December 31, 2014, respectively	16,822	16,203
Additional paid-in capital	94,618,263	92,537,742
Accumulated deficit	-77,704,306	-70,042,714
Total stockholders' equity	16,930,779	22,511,231
Total liabilities and stockholders' equity	$24,547,289	$29,723,724

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Mar. 31, 2015	Dec. 31, 2014
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	45,714,286	45,714,286
Common stock, shares issued	16,821,243	16,202,689
Common stock, shares outstanding	16,821,243	16,202,689

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenue, net of returns, allowances and discounts	$2,113,564	$590,575
Cost of revenues	1,207,064	631,699
Gross profit (loss)	906,500	-41,124
Operating expenses
Selling, general and administrative, (inclusive of stock-based compensation of $1,940,912 and $5,144,315 for the three months ended March 31, 2015 and 2014 - see Note 8)	6,529,941	8,646,544
Acquisition-related expenses	1,945,789	65,982
Change in fair value of contingent consideration liability	107,536	0
Total operating expenses	8,583,266	8,712,526
Loss from operations	-7,676,766	-8,753,650
Other income (expense)
Interest expense	0	-292
Interest income	5,967	4,547
Change in value of warrant liability	12,042	-283,267
Total other income (expense)	18,009	-279,012
Loss before income tax provision	-7,658,757	-9,032,662
Income tax provision	2,835	3,500
Net loss	($7,661,592)	($9,036,162)
Basic and diluted net loss per common share (in dollars per share)	($0.48)	($0.73)
Weighted average shares used in computing basic and diluted net loss per common share (in shares)	16,068,562	12,356,096

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Parenthetical] (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Allocated Share-based Compensation Expense	$1,940,912	$5,144,315

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2014	$22,511,231	$16,203	$92,537,742	($70,042,714)
Balance (in shares) at Dec. 31, 2014		16,202,689
Exercise of common stock options	236,278	54	236,224	0
Exercise of common stock options (in shares)		53,986
Stock-based compensation	2,032,512	600	2,031,912	0
Stock-based compensation (in shares)		600,000
Net settlement on vesting of restricted stock awards	-187,650	-35	-187,615	0
Net settlement on vesting of restricted stock awards (in shares)		-35,432
Net loss	-7,661,592	0	0	-7,661,592
Balance at Mar. 31, 2015	$16,930,779	$16,822	$94,618,263	($77,704,306)
Balance (in shares) at Mar. 31, 2015		16,821,243

CONDENSED_CONSOLIDATED_STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Operating Activities
Net loss	($7,661,592)	($9,036,162)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	311,162	185,213
Amortization of deferred lease incentive	-2,085	-2,084
Deferred income taxes	2,835	3,500
Provision for inventory obsolescence	-478	-22,545
Stock-based compensation expense	2,032,512	5,013,205
Stock issued for services rendered	0	148,320
Change in value of warrant liability	-12,042	283,267
Fair value adjustment to contingent consideration	107,536	0
Changes in operating assets and liabilities:
Accounts receivable	-434,979	-7,219
Inventory	-189,501	22,943
Prepaid expenses and other current assets	-336,454	-50,232
Accounts payable	44,756	11,158
Accrued expenses and other current liabilities	263,017	835,122
Net Cash Used in Operating Activities	-5,875,313	-2,615,514
Investing Activities
Payment for distribution rights	0	-100,000
Purchase of improvements and equipment	-5,000	-6,596
Net Cash Used in Investing Activities	-5,000	-106,596
Financing Activities
Proceeds from the exercise of stock options	236,278	469,550
Payment of withholding taxes related to stock-based employee compensation	-187,650	-201,174
Net Cash Provided by Financing Activities	48,628	268,376
Net Decrease in Cash and Cash Equivalents	-5,831,685	-2,453,734
Cash and Cash Equivalents - Beginning of period	16,770,879	12,100,544
Cash and Cash Equivalents - End of period	10,939,194	9,646,810
Supplemental Disclosure of Cash Flows Information
Cash paid during the period for Interest	0	282
Non-cash investing and financing activities:
Cashless warrant exercise	0	672,632
2013 Bonus awarded in equity	$0	$307,189

Description_of_Business_and_Ba

Description of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Description and Basis of Presentation [Text Block]		1	Description of Business and Basis of Presentation
	Alliqua BioMedical, Inc. (the “Company”) is a provider of advanced wound care solutions. The Company’s primary business strategy is to create superior outcomes for patients, providers, and partners through its hydrogel technology platform and licensed and proprietary products.  The Company’s core businesses include advanced wound care and contract manufacturing. The Company seeks to leverage its proprietary hydrogel and licensed technology platform to add value to its own products and those of its partners.
	Basis of Presentation
	The condensed consolidated financial statements contained in this report are unaudited. In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the Company’s financial position as of March 31, 2015 and results of operations for the three months ended March 31, 2015, and cash flows for the three months ended March 31, 2015. While management believes that the disclosures presented are adequate to make the information not misleading, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto in the Company’s latest year-end financial statements, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 (the “2014 Annual Report”).  The results of the Company’s operations for any interim period are not necessarily indicative of the results of operations for any other interim period or for the full year.
	Principles of Consolidation
	The accompanying condensed consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries, AquaMed Technologies, Inc., HepaLife Biosystems, Inc., Alliqua BioMedical SUB, Inc., ALQA Cedar Inc. and Choice Therapeutics, Inc. All significant inter-company transactions and accounts have been eliminated in consolidation.
	Reclassifications
	Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such reclassifications did not have a material effect on the Company’s financial condition or results of operations as previously reported.
	Significant Accounting Policies and Estimates
	The Company’s significant accounting policies are disclosed in Note 2 — Summary of Significant Accounting Policies in the 2014 Annual Report. Since the date of the 2014 Annual Report, there have been no material changes to the Company’s significant accounting policies. The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. These estimates and assumptions include valuing equity securities and derivative financial instruments issued in financing transactions, inventory reserves, deferred taxes and related valuation allowances, and the fair values of long lived assets, intangibles, goodwill and contingent consideration. Actual results could differ from the estimates.
	Recent Accounting Pronouncements
	In May 2014, the FASB issued a new revenue recognition standard entitled “Revenue from Contracts with Customers” under Accounting Standards Update 2014-09.  The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. The standard is effective for annual reporting periods beginning after December 15, 2017, which for the Company will commence with the year beginning January 1, 2018.  Earlier application is not permitted.  Entities must adopt the new guidance using one of two retrospective application methods. The Company is currently evaluating the standard to determine the impact of its adoption on the consolidated financial statements.
	In June 2014, the FASB issued Accounting Standards Update 2014-12, “Compensation — Stock Compensation: Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period” (“ASU 2014-12”).  ASU 2014-12 requires that a performance target that affects vesting of share-based payments and that could be achieved after the requisite service period be treated as a performance condition that affects vesting and as such, should not be reflected in estimating the grant-date fair value of the award.  ASU 2014-12 is effective for annual and interim periods beginning after December 15, 2015.  This standard is not expected to have a material effect on the Company’s financial position, results of operations or cash flows.

Net_Loss_Per_Common_Share

Net Loss Per Common Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	2. Net Loss Per Common Share
	Basic net loss per common share is computed based on the weighted average number of shares of common stock outstanding during the periods presented. Common stock equivalents, consisting of stock options, warrants and non-vested restricted stock, were not included in the calculation of the diluted loss per share because their inclusion would have been anti-dilutive.
	The total common shares issuable upon the exercise of stock options, warrants and non-vested restricted stock are as follows:
		As of March 31,
		2015	2014
	Stock options	5,522,507	4,907,284
	Warrants	2,675,121	3,652,194
	Non-vested restricted stock	741,975	329,096
	Total	8,939,603	8,888,574

Acquisitions

Acquisitions	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	3	Acquisitions
	Acquisition of Choice Therapeutics, Inc.
	On May 5, 2014, the Company acquired all outstanding equity interest of Choice Therapeutics, Inc., a provider of innovative wound care products using proprietary TheraBond 3D® Antimicrobial Barrier Systems. The Company’s initial cash payment for this acquisition was $2.0 million and approximately $2.0 million in common stock. In addition to the initial cash payment, the Company may pay up to $5.0 million in contingent consideration which may be earned based upon the acquired company achieving specific performance metrics over the three twelve month periods, ended April 30, 2017. See Note 11 – Fair Value Measurement for details related to fair value of the contingent consideration.
	The assets and liabilities of the acquired business were included in the Company’s condensed consolidated balance sheet based upon estimated fair values on the date of acquisition as determined in the purchase price allocation, using available information and making assumptions management believes are reasonable. The Company’s allocation of purchase price for this acquisition is included in the table below, which summarizes the estimated fair value of the assets acquired and liabilities assumed at the date of acquisition:
	Consideration:
	Common stock		$	1,992,854
	Cash paid			2,000,000
	Fair value of contingent consideration			2,700,000
	Total consideration			6,692,854
	Cash			474
	Inventory			396,961
	Other assets			11,587
	Tradenames			111,000
	Technology			2,396,000
	Customer relationships			176,000
	Goodwill			3,674,326
	Other liabilities			-73,494
	Net assets acquired		$	6,692,854
	The amortization period of intangible assets acquired ranges from 3 to 12 years. The Company recorded approximately $3.7 million of goodwill in connection with this acquisition, reflecting the strategic fit and revenue and earnings growth potential of this business.
	The following unaudited pro forma results of operations for the three months ended March 31, 2014 assumes that the above acquisition was made at the beginning of the year prior to the acquisition. The pro forma results were calculated applying the Company’s accounting policies and reflect the elimination of transaction costs related to the acquisition that were included in the Company’s results of operations for the three months ended March 31, 2014. The unaudited pro forma information does not purport to be indicative of the results that would have been obtained if the acquisition had actually occurred at the beginning of the year prior to acquisition, nor of the results that may be reported in the future.
			Pro forma Results for the
			Three Months Ended March 31, 2014
	Revenues		$	1,051,209
	Net loss		$	-9,408,466
	Acquisition of Celleration, Inc.
	On February 2, 2015, the Company entered in an Agreement and Plan of Merger (“the Merger Agreement”) with AlQA Cedar, Inc., a wholly-owned subsidiary of the Company, and Celleration, Inc. The Merger Agreement provides for an initial aggregate purchase price of $30,415,000 payable in equal amounts of cash and the Company’s common stock. In connection with the Merger Agreement, the Company received a commitment letter from a lender in which the lender has committed to provide the Company with a senior, secured term loan facility in the amount of $15,500,000, pursuant to the terms of the commitment letter. The Company expects to use the proceeds from this loan facility to provide the capital for the upfront cash portion associated with the consummation of the Merger Agreement. The Merger Agreement may be terminated by either party if the merger is not completed by May 31, 2015, provided that the Company may extend that date to July 31, 2015 in certain circumstances so long as the Company can provide Celleration with a $1,000,000 loan by May 15, 2015. The Merger Agreement also contains customary termination provisions which would require the Company to pay a termination fee of $3,000,000, less any amounts loaned to Celleration, if the Merger Agreement is terminated by (i) the Company or Celleration for the Company’s failure to obtain the required approval of the Company’s stockholders or (ii) Celleration for the Company’s failure to secure the required financing. Celleration is required to pay the Company a termination fee of $4,000,000 if Celleration terminates the Merger Agreements in order to accept a superior proposal as defined in the Merger Agreement.
	Celleration focuses on developing and commercializing therapeutic ultrasound healing technologies, including the MIST Therapy System® and UltraMIST®, which deliver noncontact low-frequency, low-intensity ultrasound to the wound bed through a saline mist. The merger is expected to close during the second quarter of 2015, subject to the receipt of any required approvals and the satisfaction or waiver of the conditions to the merger contained in the Merger Agreement. However, it is possible that factors outside the control of the parties could require the parties to complete the merger at a later time or not complete it at all. During the three months ended March 31, 2015, the Company incurred acquisition-related costs of approximately $1,946,000 in connection with due diligence, professional fees, and other expenses related to Celleration.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	4	Inventory
	Inventory consists of the following:
			March 31,		December 31,
			2015		2014
	Raw materials		$	220,378	$	197,514
	Work in process			546,419		489,431
	Finished goods			835,546		725,897
	Less: Inventory reserve			-616		-1,094
	Total		$	1,601,727	$	1,411,748

Intangible_Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	5	Intangible Assets
	The gross carrying amount and accumulated amortization of intangible assets are as follows:
				March 31, 2015
			Useful Life	Gross		Accumulated		Net
			(Years)	Amount		Amortization		Carrying
								Amount
	Technology		10	$	5,396,000	$	-2,069,633	$	3,326,367
	Customer relationships		12-Sep		776,000		-326,260		449,740
	Distribution rights		5.27		400,000		-115,928		284,072
	Tradename		3		111,000		-33,916		77,084
	Non-compete		1		208,333		-190,972		17,361
				$	6,891,333	$	-2,736,709	$	4,154,624
				December 31, 2014
			Useful Life	Gross		Accumulated		Net
			(Years)	Amount		Amortization		Carrying
								Amount
	Technology		10	$	5,396,000	$	-1,934,733	$	3,461,267
	Customer relationships		12-Sep		776,000		-308,871		467,129
	Distribution rights		5.27		400,000		-96,880		303,120
	Tradename		3		111,000		-24,667		86,333
	Non-compete		1		208,333		-138,889		69,444
				$	6,891,333	$	-2,504,040	$	4,387,293
	Amortization expense attributable to intangible assets for the three months ended March 31, 2015 and 2014 was $232,669 and $106,548, respectively. Amortization expense for the years ended December 31, 2015, 2016, 2017, 2018 and 2019 is expected to be $791,790, $722,346, $697,679, $683,704, and $334,156, respectively.

Accrued_Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2015
Accrued Liabilities, Current [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6	Accrued Expenses
	Accrued expenses consist of the following:
			March 31,		December 31,
			2015		2014
	Salaries, benefits and incentive compensation		$	1,495,878	$	1,528,229
	Professional fees			494,030		228,426
	Royalty fees			173,016		100,537
	Deferred revenue			78,000		78,523
	Deferred lease incentive liability			8,337		8,337
	Other			81,615		123,807
	Total accrued expenses and other current liabilities		$	2,330,876	$	2,067,859

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]		7	Commitments and Contingencies
	License Agreement
	On July 15, 2011, the Company entered into a license agreement with Noble Fiber Technologies, LLC, whereby the Company has the exclusive right and license to manufacture and distribute “SilverSeal Hydrogel Wound Dressings” and “SilverSeal Hydrocolloid Wound Dressings”. The license is granted for ten years with an option to be extended for consecutive renewal periods of two years after the initial term. Royalties are to be paid equal to 9.75% of net sales of licensed products. The agreement calls for minimum royalties to be paid each calendar year as follows: 2015 - $500,000; and 2016 - $600,000. Total royalties charged to selling, general and administrative expense for the three months ended March 31, 2015 and 2014 were $125,000 and $100,000, respectively. $1,219 is included in accounts payable and $123,781 is included in accrued expenses as of March 31, 2015 in connection with this agreement.
	Sorbion Distributor Agreement
	On September 23, 2013, the Company entered into a distributor agreement (the “Sorbion Agreement”) with Sorbion GmbH & Co KG, pursuant to which the Company became the exclusive distributor of sorbion sachet S, sorbion sana and new products with hydrokinetic fibers as primary dressings in the United States, Canada and Latin America, subject to certain exceptions. The term of the agreement ends on December 31, 2018.
	In order to maintain its exclusivity, the Company must purchase the following minimum amounts, in Euros, of the products for the indicated calendar year:
	Calendar Year		Minimum Annual Purchase Amount
	2015		1,000,000 Euros
	2016		2,500,000 Euros
	2017		4,000,000 Euros
	Since the Company must purchase the minimum amounts in Euros, the equivalent U.S. dollar expenditure will be subject to fluctuations in foreign currency exchange rates. The minimum annual purchase amounts in U.S. Dollars for each calendar year in the period from 2015-2017, based on the exchange rate as of March 31, 2015, are approximately $1,085,010, $2,712,530, and $4,340,040, respectively.
	If the Company fails to purchase products in amounts that meet or exceed the minimum annual purchase amount for a calendar year, it may cure such minimum purchase failure by paying Sorbion in cash an amount equal to the minimum annual purchase amount for such calendar year less the amount the Company paid to Sorbion for the products purchased for such calendar year.  If the Company does not cure a minimum purchase failure with a makeup payment for a calendar year, Sorbion may terminate the Company’s exclusivity with respect to the products and grant the Company non-exclusive rights with respect to the products.  If the Company does not cure a minimum purchase failure for two subsequent calendar years, Sorbion may terminate the agreement.  The Company will not be required to meet the minimal annual purchase amount if Sorbion fails to supply the Company with the products in accordance with the agreement.  Sorbion may also terminate the Company’s exclusivity with respect to the products if the Company does not cure a material breach of the agreement within 30 days. The Company has the right to use the trademarks related to the products. The Company has the ability to sell the products under their respective trademarked names and at prices determined by the Company.   The Company is eligible for certain discounts with respect to the purchase and shipping of the products if its orders of the products are above certain amounts.
	Celgene License, Marketing and Development and Supply Agreement
	In November 2013, the Company entered into a License, Marketing and Development Agreement (the “License Agreement”) with Anthrogenesis Corporation, d/b/a Celgene Cellular Therapeutics (“CCT”), an affiliate of Celgene Corporation (“Celgene”), pursuant to which CCT granted the Company an exclusive, royalty-bearing license in its intellectual property for certain placental based products, including ECMs, an extracellularmatrix derived from the human placenta, and Biovance®, CCT’s proprietary wound coverings produced from decellularized, dehydrated human amniotic membrane, to develop and commercialize ECMs and Biovance in the United States. Following the commencement of commercial sales of the licensed products, the Company will pay CCT annual license fees, designated amounts when certain milestone events occur and royalties on all sales of licensed products, with such amounts being variable and contingent on various factors. The initial term of the License Agreement ends on November 14, 2023, unless sooner terminated pursuant to the termination rights under the License Agreement, and will extend for additional two-year terms unless either party gives written notice within a specified period prior to the end of a term. The License Agreement may be terminated (i) by CCT if the Company or any of its affiliates challenges the validity, enforceability or scope of certain enumerated CCT patents anywhere in the world; (ii) by either party if there is a final decree that a licensed product infringed on the intellectual property of a third party; (iii) by either party for breach of the License Agreement, if the breach is not cured within a specified period after receiving written notice of the breach; or (iv) by either party if the other party is the subject of insolvency proceedings, either voluntary or involuntary. In addition, the License Agreement is terminable on a product-by-product basis, and not with respect to the entire License Agreement (i) by CCT in the second year of the License Agreement, and by either CCT or the Company in the third year of the License Agreement and beyond, if the Company fails to meet certain sales thresholds and (ii) by either party upon written notice if outside legal counsel recommends discontinuance of commercialization of a product because of significant safety, legal, or economic risk as a result of a claim, demand or action or as a result of a change in the interpretation of law by a governmental or regulatory authority. The License Agreement also contains mutual confidentiality and indemnification obligations for the Company and CCT. In September 2014, the Company entered into a First Amendment to the License Agreement (the “Amended License Agreement”), pursuant to which the Company received the right to market Biovance for podiatric and orthopedic applications. The Amended License Agreement also amends certain terms and the related schedule for milestone payments to CCT.
	In November 2013, the Company also entered into a Supply Agreement (the “Biovance Supply Agreement”) with CCT, pursuant to which CCT shall supply the Company with the Company’s entire requirements of Biovance for distribution and sale in the United States. The Biovance Supply Agreement will be terminated automatically upon the termination of the License Agreement and may otherwise be terminated (i) by CCT upon six months’ prior written notice, (ii) by the Company upon six months’ prior written notice if CCT fails to deliver at least a specified portion of a firm purchase order by the required delivery date specified in the order on at least a specified number of occasions in a specified period; (iii) by either party for breach of the Biovance Supply Agreement, if the breach is not cured within a specified period after receiving written notice of the breach; or (iv) by either party if the other party is the subject of insolvency proceedings, either voluntary or involuntary. On April 10, 2014, the Company and CCT entered into an amendment to the Biovance Supply Agreement in order to amend the pricing schedule.
	In April 2014, the Company entered into a Supply Agreement (the “ECM Supply Agreement”) with CCT, pursuant to which CCT shall, as soon as reasonably practicable after the date that CCT obtains regulatory clearance or approval in the United States for any of CCT’s extracellular matrix products derived from the human placenta (each an “ECM”), supply and sell to the Company all of the Company’s requirements of ECMs, in finished form and final packaging, for exploitation in the United States under the License Agreement. The ECM Supply Agreement will automatically terminate upon the termination or expiration of the License Agreement and may otherwise be terminated (i) by CCT upon six months’ prior written notice, (ii) by the Company upon six months’ prior written notice if CCT fails to deliver at least a specified portion of a firm purchase order by the required delivery date specified in the order on at least a specified number of occasions in a specified period; (iii) by either party for breach of the ECM Supply Agreement, if the breach is not cured within a specified period after receiving written notice of the breach; or (iv) by either party if the other party is the subject of insolvency proceedings, either voluntary or involuntary. The ECM Supply Agreement also contains mutual confidentiality and indemnification obligations for the Company and CCT.
	Senior Secured Term Loan Facility
	In connection with the Merger Agreement with Celleration, the Company entered into a commitment letter, dated as of February 2, 2015 (the “Commitment Letter”), with Perceptive Credit Opportunities Fund, LP (“Perceptive”), pursuant to which Perceptive has committed to provide the Company with a senior, secured term loan facility in the aggregate amount of $15,500,000, pursuant to the terms and conditions of the Commitment Letter and the term sheet annexed thereto (the “Debt Financing”). Pursuant to the Commitment Letter, the Debt Financing will (i) have a four year term, (ii) accrue interest at an annual rate equal to (a) the greater of one-month LIBOR or 1% plus (b) 9.75%, (iii) be interest only for the first 24 months, followed by monthly amortization payments of $225,000, with the remaining unpaid balance due on the maturity date and (iv) be secured by a first priority lien on substantially all of the Company’s assets. The Company expects to use the funds from the Debt Financing to fund the upfront cash portion of the purchase price and other expenses associated with the consummation of the transactions contemplated by the Merger Agreement. On March 10, 2015, the Commitment Letter was amended to extend the expiration time of Perceptive’s commitments and agreements under the Commitment Letter to May 31, 2015, unless the Company extends the “Outside Date” as defined in that certain Agreement and Plan of Merger, dated February 2, 2015 (the “Merger Agreement”), by and among the Company, Alliqua Cedar, Inc., Celleration, Inc. and certain representatives of Celleration stockholders, in accordance with the terms and conditions set forth therein, in which case such time shall automatically be extended to July 31, 2015 (“the Extended Expiration Time”). Accordingly, Perceptive’s commitments and agreements with respect to the senior, secured term loan facility described in the Commitment Letter, as amended, will automatically terminate at the Extended Expiration Time if the conditions precedent set forth in the definitive credit documentation described below have not been satisfied.
	In addition, on March 10, 2015, the Company and Perceptive agreed on a form of Credit Agreement and Guaranty (the “Credit Agreement”) to be entered into by the Company, each of its subsidiaries and Perceptive upon the satisfaction of certain conditions precedent set forth in the Credit Agreement prior to the Extended Expiration Time, which are the same conditions to Perceptive’s obligation to fund the term loan under the Credit Agreement. These conditions include, among other things: the contemporaneous consummation of the merger on the terms and conditions set forth in the Merger Agreement (the “Merger”); the receipt by Perceptive of a promissory note evidencing the full amount of the loan and related loan documentation evidencing the security interests granted therein, a five-year warrant to purchase 750,000 shares of the Company’s common stock, certain financial statements, documentation for the perfection of security interests, various closing certificates and opinions of counsel to the Company; the Company’s payment of all fees due and payable to Perceptive under the Credit Agreement as of the closing date of the Merger (the “Closing Date”) and miscellaneous other closing conditions that are customary for credit facilities and transactions of this type.
	The Credit Agreement will require the Company to prepay the outstanding principal amount of the term loan with 100% of the net cash proceeds received from specified asset sales, issuances or sales of equity and incurrences of borrowed money indebtedness, subject to certain exceptions. The Company will also incur an incremental fee for any repayments or prepayments other than the required monthly principal payments made prior to the third anniversary of the Closing Date. The Company will also be required to pay an exit fee when the term loan is paid in full equal to the greater of 1% of the outstanding principal balance immediately prior to the final payment and $100,000.
	The Credit Agreement contains customary affirmative and negative covenants and events of default for a secured financing arrangement, including limitations on additional indebtedness, liens, asset sales and acquisitions, among others. In addition to other customary events of default, any termination of that certain License, Marketing and Development Agreement between the Company and CCT, as amended, will constitute an event of default under the Credit Agreement.
	Litigation, Claims and Assessments
	The Company is subject to periodic lawsuits, investigations and claims that arise in the ordinary course of business. The Company is not party to any material litigation as of March 31, 2015.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2015
Stockholders Equity Note [Abstract]
Stockholders Equity Note Disclosure [Text Block]	8	Stockholders’ Equity
	2011 Plan
	The Company maintains the 2011 Long-Term Incentive Plan (the “2011 Plan”) that provides for the granting of stock options, RSUs, restricted stock and other awards to employees, directors and others. A total of 1,828,571 shares of common stock have been authorized for issuance under the 2011 Plan, of which, as of March 31, 2015, 62,777 shares were available for future issuances.
	2014 Plan
	On April 10, 2014 and June 5, 2014, the Company’s Board of Directors and the Company’s shareholders approved the 2014 Long-Term Incentive Plan (the “2014 Plan”), respectively. The 2014 Plan provides for the granting of stock options, RSUs, restricted stock and other awards to employees, directors and others. A total of 2,000,000 shares of common stock are reserved for award under the 2014 Plan, of which, as of March 31, 2015, 371,000 shares were available for future issuances.
	Stock-Based Compensation
	The following table summarizes stock-based compensation expense:
			Three Months Ended March 31,
			2015			2014
	Options		$	1,530,541		$	3,464,956
	Warrants			-			197,792
	Restricted stock units			-			180,715
	Restricted stock			501,971			1,318,062
	Total stock-based compensation		$	2,032,512		$	5,161,525
	For the three months ended March 31, 2015, $91,600 of stock-based compensation expense is included in cost of revenues and $1,940,912 is included in selling, general and administrative expenses in the condensed consolidated statements of operations. For the three months ended March 31, 2014, $17,210 of stock-based compensation expense is included in cost of revenues and $5,144,315 is included in selling, general and administrative expenses in the condensed consolidated statements of operations.
	Restricted Stock
	The following table summarizes the restricted stock issued as compensation during the three months ended March 31, 2015:
	Issuance		Grantee		Shares		Vesting		Grant Date
	Date		Type		Issued		Term		Value
	2/6/15		Officers		600,000		[1]		3,738,000
			2015 - Restricted Stock - Total		600,000				3,738,000
		[1]	Vests in three equal annual installments, with one-third vesting on each of February 6, 2016, February 6, 2017 and February 6, 2018.
	As of March 31, 2015, there was $3,563,477 of unrecognized stock-based compensation expense related to restricted stock which will be amortized over a weighted average period of 1.8 years.
	A summary of common stock award activity during the three months ended March 31, 2015 is presented below:
			Number of		Weighted			Total Grant
			Shares		Average			Date Fair
					Grant Date			Value
					Fair Value
	Non-vested, December 31, 2014		188,149		$	7.03		$	1,322,096
	Granted		600,000			6.23			3,738,000
	Vested		-46,174			6.99			-322,756
	Forfeited		-			-			-
	Non-vested, March 31, 2015		741,975		$	6.38		$	4,737,340
	Warrants
	There were no compensatory warrants issued during the three months ended March 31, 2015.
	As of March 31, 2015, there was no unrecognized stock-based compensation expense related to compensatory warrants.
	A summary of the warrant activity during the three months ended March 31, 2015 is presented below:
			Number of		Weighted			Weighted		Intrinsic Value
			Warrants		Average			Average
					Exercise			Remaining
					Price			Life in
								Years
	Outstanding, December 31, 2014		2,675,121		$	5.76
	Issued		-			-
	Exercised		-			-
	Cancelled		-			-
	Outstanding, March 31, 2015		2,675,121		$	5.76		3.4		$	1,399,606
	Exercisable, March 31, 2015		2,675,121		$	5.76		3.4		$	1,399,606
	The following table presents information related to warrants at March 31, 2015:
	Warrants Outstanding					Warrants Exercisable
	Exercise Price			Outstanding		Weighted		Exercisable
				Number of		Average		Number of
				Warrants		Remaining		Warrants
						Life in
						Years
	$	2.19		108,572		2.5		108,572
		3.02		74,286		1.9		74,286
		3.5		2,286		2.1		2,286
		4.24		780,191		3.2		780,191
		4.38		188,444		3.6		188,444
		4.81		8,889		3.6		8,889
		5.69		1,040,880		3.6		1,040,880
		7		18,286		0.1		18,286
		8.75		25,429		0.3		25,429
	10.5		427,858		4		427,858
			2,675,121		3.4		2,675,121
As of March 31, 2015, five-year warrants to purchase an aggregate of 75,429 shares of common stock at an exercise price of $2.19 per share were deemed to be a derivative liability. See Note 11 – Fair Value Measurement.
Stock Options
Options – 2015 Grants
During the three months ended March 31, 2015, ten-year options to purchase an aggregate of 795,500 shares of common stock at exercise prices ranging from $5.01 to $6.23 with an aggregate grant date value of $3,834,816 were granted to employees. Options to purchase an aggregate of 791,000 shares of common stock were granted pursuant to the 2014 Plan and vest ratably over three years on the anniversaries of the grant date. Options to purchase an aggregate of 4,500 shares of common stock were granted pursuant to the 2011 Plan and vested immediately. The grant date value is being amortized over the vesting term.
Options – Summary Data
In applying the Black-Scholes option pricing model to stock options granted, the Company used the following weighted average assumptions:
		Three Months Ended March 31,
		2015		2014
Risk free interest rate		1.67	%	1.9	%
Expected term (years)		6		5.92
Expected volatility		98.25	%	102.63	%
Expected dividends		0	%	0	%
The risk-free interest rate is based on rates of treasury securities with the same expected term as the options. The Company uses the "simplified method" to calculate the expected term of employee and director stock-based options. The expected term used for consultants is the contractual life. The Company is utilizing an expected volatility figure based on a review of the Company’s historical volatility, over a period of time, equivalent to the expected life of the instrument being valued. The expected dividend yield is based upon the fact that the Company has not historically paid dividends, and does not expect to pay dividends in the near future.
Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The Company estimated forfeitures related to options at annual rates ranging from 0% to 5% for options outstanding at March 31, 2015.
The weighted average estimated fair value per share of the options granted during the three months ended March 31, 2015 and 2014 was $4.82 and $6.58, respectively.
During the three months ended March 31, 2015, the Company issued an aggregate of  53,986 shares of common stock to several holders of options who elected to exercise options to purchase an aggregate of  53,986 shares of common stock for cash proceeds of $236,278. The options had an exercise price of $4.38 per share. The aggregate intrinsic value of the options exercised was $67,156 for the three months ended March 31, 2015.
As of March 31, 2015, there was $7,403,090 of unrecognized stock-based compensation expense related to stock options which will be amortized over a weighted average period of 1.7 years, of which $74,524 is subject to non-employee mark-to-market adjustments.
A summary of the stock option activity during the three months ended March 31, 2015 is presented below:
		Number of		Weighted			Weighted		Intrinsic Value
		Options		Average			Average
				Exercise			Remaining
				Price			Life in
							Years
Outstanding, December 31, 2014		4,817,660		$	6.56
Granted		795,500			6.17
Exercised		-53,986			4.38
Forfeited		-36,667			6.59
Outstanding, March 31, 2015		5,522,507		$	6.52		8		$	1,603,929
Exerciseable, March 31, 2015		2,620,641		$	5.91		6.9		$	1,395,540
The following table presents information related to stock options at March 31, 2015:
		Options Outstanding					Options Exercisable
Range of		Weighted			Outstanding		Weighted Average			Weighted	Exercisable
Exercise Price		Average			Number of		Exercise Price			Average	Number of
		Exercise			Options					Remaining	Options
		Price								Life in Years
$3.28-$3.99		$	3.4		433,971		$	3.36		8.1	403,971
$4.00-$4.99			4.42		1,038,415			4.38		4.1	792,704
$5.00-$5.99			5.4		355,427			5.52		6.9	127,960
$6.00-$6.99			6.59		2,277,677			6.76		8.5	750,608
$7.00-$7.99			7.75		31,000			-		-	-
$8.00-$8.99			8.74		800,898			8.75		7.8	390,293
$9.00-$9.99			9.01		321,500			9		8.9	117,161
$10.00-$26.69			10.96		263,619			11.05		7.9	37,944
					5,522,507					6.9	2,620,641

Related_Party

Related Party	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	9	Related Party
	On January 6, 2014, the Company entered into an option cancellation and release agreement with two former directors, pursuant to which each of the parties agreed to cancel options previously granted to purchase 278,096 shares of common stock of the Company at exercise prices ranging from $6.34 to $9.19.  In exchange for the cancellation of the options, the Company granted each individual 194,667 shares of common stock of the Company pursuant to the 2011 Plan. The incremental expense for the exchange was $98,915 and is included in stock-based compensation in the three months ended March 31, 2014.

Concentration_of_Risk

Concentration of Risk	3 Months Ended
	Mar. 31, 2015
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	10	Concentration of Risk
	Revenue for the three months ended March 31, 2015 and 2014, and accounts receivable as of March 31, 2015 from our largest customers, both contract manufacturing customers, are as follows:
			% of Total Revenue				Accounts Receivable
	Customer		2015		2014		March 31, 2015
	A		26	%	55	%	23	%
	B		0	%	11	%	0	%

Fair_Value_Measurement

Fair Value Measurement	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	11	Fair Value Measurement
	Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are as follows:
	Level 1: Observable prices in active markets for identical assets and liabilities.
	Level 2: Observable inputs other than quoted prices in active markets for identical assets and liabilities.
	Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.
	On March 31, 2015, the Company recomputed the fair value of its warrant liability to purchase an aggregate of 75,429 shares of common stock as $292,181 using the Binomial option pricing model (Level 3 inputs) using the following assumptions: expected volatility of  98.25%, risk-free rate of  0.89%, expected term of  2.61 years, and expected dividends of  0.00%. The Company recorded a gain on the change in fair value of these warrant liabilities of $12,042 during the three months ended March 31, 2015.
	The following table sets forth a summary of the changes in the fair value of Level 3 warrant liabilities that are measured at fair value on a recurring basis:
			Three Months Ended March 31,
			2015		2014
	Warrant Liabilities
	Beginning balance		$	304,223	$	933,465
	Change in fair value of warrant liability			-12,042		283,267
	Value of warrants exercised			-		-672,632
	Ending balance		$	292,181	$	544,100
			Three Months Ended March 31, 2015
	Contingent Consideration
	Beginning balance		$	2,931,598
	Change in fair value of contingent consideration			107,536
	Ending balance		$	3,039,134
	Assets and liabilities measured at fair value on a recurring or nonrecurring basis are as follows:
			March 31, 2015
			Level 1		Level 2		Level 3
	Liabilities:
	Warrant liabilities		$	-	$	-	$	292,181
	Contingent consideration			-		-		3,039,134
	Total liabilities		$	-	$	-	$	3,331,315
			December 31, 2014
			Level 1		Level 2		Level 3
	Liabilities:
	Warrant liabilities		$	-	$	-	$	304,223
	Contingent consideration			-		-		2,931,598
	Total liabilities		$	-	$	-	$	3,235,821
	Warrants that contain exercise reset provisions and contingent consideration liabilities are Level 3 derivative liabilities measured at fair value on a recurring basis using pricing models for which at least one significant assumption is unobservable as defined in ASC 820. The fair value of contingent consideration liabilities that was classified as Level 3 in the table above was estimated using a discounted cash flow technique with significant inputs that are not observable in the market and thus represents a Level 3 fair value measurement as defined in ASC 820. The significant inputs in the Level 3 measurement not supported by market activity include the probability assessments of expected future cash flows related to the acquisitions, appropriately discounted considering the uncertainties associated with the obligation, and as calculated in accordance with the terms of the acquisition agreements. The development and determination of the unobservable inputs for Level 3 fair value measurements and the fair value calculations are the responsibility of the Company’s chief financial officer and are approved by the chief executive officer.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	12	Subsequent Events
	On May 4, 2015, the Company closed an underwritten public offering of 7,582,418 shares of its common stock at a price to the public of $4.55 per share. Proceeds from this offering, net of underwriter fees were $32,430,000. The Company intends to use the net proceeds from this offering to fund the commercial expansion of its marketed products, to pursue additional product platforms, and for working capital and general corporate purposes. The shares of common stock were issued pursuant to the Company’s shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission and declared effective on September 25, 2014.

Description_of_Business_and_Ba1

Description of Business and Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation
	The condensed consolidated financial statements contained in this report are unaudited. In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the Company’s financial position as of March 31, 2015 and results of operations for the three months ended March 31, 2015, and cash flows for the three months ended March 31, 2015. While management believes that the disclosures presented are adequate to make the information not misleading, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto in the Company’s latest year-end financial statements, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 (the “2014 Annual Report”).  The results of the Company’s operations for any interim period are not necessarily indicative of the results of operations for any other interim period or for the full year.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation
	The accompanying condensed consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries, AquaMed Technologies, Inc., HepaLife Biosystems, Inc., Alliqua BioMedical SUB, Inc., ALQA Cedar Inc. and Choice Therapeutics, Inc. All significant inter-company transactions and accounts have been eliminated in consolidation.
Reclassification, Policy [Policy Text Block]	Reclassifications
	Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such reclassifications did not have a material effect on the Company’s financial condition or results of operations as previously reported.
Significant Accounting Policies and Estimates [Policy Text Block]	Significant Accounting Policies and Estimates
	The Company’s significant accounting policies are disclosed in Note 2 — Summary of Significant Accounting Policies in the 2014 Annual Report. Since the date of the 2014 Annual Report, there have been no material changes to the Company’s significant accounting policies. The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. These estimates and assumptions include valuing equity securities and derivative financial instruments issued in financing transactions, inventory reserves, deferred taxes and related valuation allowances, and the fair values of long lived assets, intangibles, goodwill and contingent consideration. Actual results could differ from the estimates.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements
	In May 2014, the FASB issued a new revenue recognition standard entitled “Revenue from Contracts with Customers” under Accounting Standards Update 2014-09.  The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. The standard is effective for annual reporting periods beginning after December 15, 2017, which for the Company will commence with the year beginning January 1, 2018.  Earlier application is not permitted.  Entities must adopt the new guidance using one of two retrospective application methods. The Company is currently evaluating the standard to determine the impact of its adoption on the consolidated financial statements.
	In June 2014, the FASB issued Accounting Standards Update 2014-12, “Compensation — Stock Compensation: Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period” (“ASU 2014-12”).  ASU 2014-12 requires that a performance target that affects vesting of share-based payments and that could be achieved after the requisite service period be treated as a performance condition that affects vesting and as such, should not be reflected in estimating the grant-date fair value of the award.  ASU 2014-12 is effective for annual and interim periods beginning after December 15, 2015.  This standard is not expected to have a material effect on the Company’s financial position, results of operations or cash flows.

Net_Loss_Per_Common_Share_Tabl

Net Loss Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The total common shares issuable upon the exercise of stock options, warrants and non-vested restricted stock are as follows:
		As of March 31,
		2015	2014
	Stock options	5,522,507	4,907,284
	Warrants	2,675,121	3,652,194
	Non-vested restricted stock	741,975	329,096
	Total	8,939,603	8,888,574

Acquisitions_Tables

Acquisitions (Tables)	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	The Company’s allocation of purchase price for this acquisition is included in the table below, which summarizes the estimated fair value of the assets acquired and liabilities assumed at the date of acquisition:
	Consideration:
	Common stock	$	1,992,854
	Cash paid		2,000,000
	Fair value of contingent consideration		2,700,000
	Total consideration		6,692,854
	Cash		474
	Inventory		396,961
	Other assets		11,587
	Tradenames		111,000
	Technology		2,396,000
	Customer relationships		176,000
	Goodwill		3,674,326
	Other liabilities		-73,494
	Net assets acquired	$	6,692,854
Business Acquisition, Pro Forma Information [Table Text Block]	The unaudited pro forma information does not purport to be indicative of the results that would have been obtained if the acquisition had actually occurred at the beginning of the year prior to acquisition, nor of the results that may be reported in the future.
		Pro forma Results for the
		Three Months Ended March 31, 2014
	Revenues	$	1,051,209
	Net loss	$	-9,408,466

Inventory_Tables

Inventory (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory consists of the following:
		March 31,		December 31,
		2015		2014
	Raw materials	$	220,378	$	197,514
	Work in process		546,419		489,431
	Finished goods		835,546		725,897
	Less: Inventory reserve		-616		-1,094
	Total	$	1,601,727	$	1,411,748

Intangible_Assets_Tables

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2015
Finite-Lived Intangible Assets, Net [Abstract]
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]	The gross carrying amount and accumulated amortization of intangible assets are as follows:
			March 31, 2015
		Useful Life	Gross		Accumulated		Net
		(Years)	Amount		Amortization		Carrying
							Amount
	Technology	10	$	5,396,000	$	-2,069,633	$	3,326,367
	Customer relationships	12-Sep		776,000		-326,260		449,740
	Distribution rights	5.27		400,000		-115,928		284,072
	Tradename	3		111,000		-33,916		77,084
	Non-compete	1		208,333		-190,972		17,361
			$	6,891,333	$	-2,736,709	$	4,154,624
			December 31, 2014
		Useful Life	Gross		Accumulated		Net
		(Years)	Amount		Amortization		Carrying
							Amount
	Technology	10	$	5,396,000	$	-1,934,733	$	3,461,267
	Customer relationships	12-Sep		776,000		-308,871		467,129
	Distribution rights	5.27		400,000		-96,880		303,120
	Tradename	3		111,000		-24,667		86,333
	Non-compete	1		208,333		-138,889		69,444
			$	6,891,333	$	-2,504,040	$	4,387,293

Accrued_Expenses_Tables

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2015
Accrued Liabilities, Current [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses consist of the following:
		March 31,		December 31,
		2015		2014
	Salaries, benefits and incentive compensation	$	1,495,878	$	1,528,229
	Professional fees		494,030		228,426
	Royalty fees		173,016		100,537
	Deferred revenue		78,000		78,523
	Deferred lease incentive liability		8,337		8,337
	Other		81,615		123,807
	Total accrued expenses and other current liabilities	$	2,330,876	$	2,067,859

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Long-term Purchase Commitment [Table Text Block]	In order to maintain its exclusivity, the Company must purchase the following minimum amounts, in Euros, of the products for the indicated calendar year:
	Calendar Year	Minimum Annual Purchase Amount
	2015	1,000,000 Euros
	2016	2,500,000 Euros
	2017	4,000,000 Euros

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2015
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	The following table summarizes stock-based compensation expense:
			Three Months Ended March 31,
			2015			2014
	Options		$	1,530,541		$	3,464,956
	Warrants			-			197,792
	Restricted stock units			-			180,715
	Restricted stock			501,971			1,318,062
	Total stock-based compensation		$	2,032,512		$	5,161,525
Nonvested Restricted Stock Shares Activity [Table Text Block]	The following table summarizes the restricted stock issued as compensation during the three months ended March 31, 2015:
	Issuance		Grantee		Shares		Vesting		Grant Date
	Date		Type		Issued		Term		Value
	2/6/15		Officers		600,000		[1]		3,738,000
			2015 - Restricted Stock - Total		600,000				3,738,000
		[1]	Vests in three equal annual installments, with one-third vesting on each of February 6, 2016, February 6, 2017 and February 6, 2018.
Schedule of Nonvested Share Activity [Table Text Block]	A summary of common stock award activity during the three months ended March 31, 2015 is presented below:
			Number of		Weighted			Total Grant
			Shares		Average			Date Fair
					Grant Date			Value
					Fair Value
	Non-vested, December 31, 2014		188,149		$	7.03		$	1,322,096
	Granted		600,000			6.23			3,738,000
	Vested		-46,174			6.99			-322,756
	Forfeited		-			-			-
	Non-vested, March 31, 2015		741,975		$	6.38		$	4,737,340
Warrant [Member]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the warrant activity during the three months ended March 31, 2015 is presented below:
			Number of		Weighted			Weighted		Intrinsic Value
			Warrants		Average			Average
					Exercise			Remaining
					Price			Life in
								Years
	Outstanding, December 31, 2014		2,675,121		$	5.76
	Issued		-			-
	Exercised		-			-
	Cancelled		-			-
	Outstanding, March 31, 2015		2,675,121		$	5.76		3.4		$	1,399,606
	Exercisable, March 31, 2015		2,675,121		$	5.76		3.4		$	1,399,606
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table presents information related to warrants at March 31, 2015:
	Warrants Outstanding					Warrants Exercisable
	Exercise Price			Outstanding		Weighted		Exercisable
				Number of		Average		Number of
				Warrants		Remaining		Warrants
						Life in
						Years
	$	2.19		108,572		2.5		108,572
		3.02		74,286		1.9		74,286
		3.5		2,286		2.1		2,286
		4.24		780,191		3.2		780,191
		4.38		188,444		3.6		188,444
		4.81		8,889		3.6		8,889
		5.69		1,040,880		3.6		1,040,880
		7		18,286		0.1		18,286
		8.75		25,429		0.3		25,429
		10.5		427,858		4		427,858
				2,675,121		3.4		2,675,121
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following weighted average assumptions:
			Three Months Ended March 31,
			2015		2014
	Risk free interest rate		1.67	%	1.9	%
	Expected term (years)		6		5.92
	Expected volatility		98.25	%	102.63	%
	Expected dividends		0	%	0	%
Employee Stock Option [Member]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the stock option activity during the three months ended March 31, 2015 is presented below:
			Number of		Weighted			Weighted		Intrinsic Value
			Options		Average			Average
					Exercise			Remaining
					Price			Life in
								Years
	Outstanding, December 31, 2014		4,817,660		$	6.56
	Granted		795,500			6.17
	Exercised		-53,986			4.38
	Forfeited		-36,667			6.59
	Outstanding, March 31, 2015		5,522,507		$	6.52		8		$	1,603,929
	Exerciseable, March 31, 2015		2,620,641		$	5.91		6.9		$	1,395,540
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table presents information related to stock options at March 31, 2015:
			Options Outstanding					Options Exercisable
	Range of		Weighted			Outstanding		Weighted Average			Weighted	Exercisable
	Exercise Price		Average			Number of		Exercise Price			Average	Number of
			Exercise			Options					Remaining	Options
			Price								Life in Years
	$3.28-$3.99		$	3.4		433,971		$	3.36		8.1	403,971
	$4.00-$4.99			4.42		1,038,415			4.38		4.1	792,704
	$5.00-$5.99			5.4		355,427			5.52		6.9	127,960
	$6.00-$6.99			6.59		2,277,677			6.76		8.5	750,608
	$7.00-$7.99			7.75		31,000			-		-	-
	$8.00-$8.99			8.74		800,898			8.75		7.8	390,293
	$9.00-$9.99			9.01		321,500			9		8.9	117,161
	$10.00-$26.69			10.96		263,619			11.05		7.9	37,944
						5,522,507					6.9	2,620,641

Concentration_of_Risk_Tables

Concentration of Risk (Tables)	3 Months Ended
	Mar. 31, 2015
Risks and Uncertainties [Abstract]
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Revenue for the three months ended March 31, 2015 and 2014, and accounts receivable as of March 31, 2015 from our largest customers, both contract manufacturing customers, are as follows:
		% of Total Revenue				Accounts Receivable
	Customer	2015		2014		March 31, 2015
	A	26	%	55	%	23	%
	B	0	%	11	%	0	%

Fair_Value_Measurement_Tables

Fair Value Measurement (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table sets forth a summary of the changes in the fair value of Level 3 warrant liabilities that are measured at fair value on a recurring basis:
		Three Months Ended March 31,
		2015		2014
	Warrant Liabilities
	Beginning balance	$	304,223	$	933,465
	Change in fair value of warrant liability		-12,042		283,267
	Value of warrants exercised		-		-672,632
	Ending balance	$	292,181	$	544,100
		Three Months Ended March 31, 2015
	Contingent Consideration
	Beginning balance	$	2,931,598
	Change in fair value of contingent consideration		107,536
	Ending balance	$	3,039,134
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Assets and liabilities measured at fair value on a recurring or nonrecurring basis are as follows:
		March 31, 2015
		Level 1		Level 2		Level 3
	Liabilities:
	Warrant liabilities	$	-	$	-	$	292,181
	Contingent consideration		-		-		3,039,134
	Total liabilities	$	-	$	-	$	3,331,315
		December 31, 2014
		Level 1		Level 2		Level 3
	Liabilities:
	Warrant liabilities	$	-	$	-	$	304,223
	Contingent consideration		-		-		2,931,598
	Total liabilities	$	-	$	-	$	3,235,821

Net_Loss_Per_Common_Share_Deta

Net Loss Per Common Share (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	8,939,603	8,888,574
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,522,507	4,907,284
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,675,121	3,652,194
Non-vested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	741,975	329,096

Acquisitions_Details

Acquisitions (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Consideration:
Goodwill	$4,100,295	$4,100,295
Choice Therapeutics, Inc. [Member]
Consideration:
Common stock	1,992,854
Cash paid	2,000,000
Fair value of contingent consideration	2,700,000
Total consideration	6,692,854
Cash	474
Inventory	396,961
Other assets	11,587
Goodwill	3,674,326
Other liabilities	-73,494
Net assets acquired	6,692,854
Choice Therapeutics, Inc. [Member] | Trade Names [Member]
Consideration:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	111,000
Choice Therapeutics, Inc. [Member] | Technology-Based Intangible Assets [Member]
Consideration:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	2,396,000
Choice Therapeutics, Inc. [Member] | Customer Relationships [Member]
Consideration:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	$176,000

Acquisitions_Details_1

Acquisitions (Details 1) (Choice Therapeutics, Inc. [Member], USD $)	3 Months Ended
	Mar. 31, 2014
Choice Therapeutics, Inc. [Member]
Business Acquisition [Line Items]
Revenues	$1,051,209
Net loss	($9,408,466)

Acquisitions_Details_Textual

Acquisitions (Details Textual) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	5-May-14
Business Acquisition [Line Items]
Business Combination, Acquisition Related Costs	$1,945,789	$65,982
Choice Therapeutics, Inc. [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability				5,000,000
Choice Therapeutics, Inc. [Member] | Minimum [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life			3 years
Choice Therapeutics, Inc. [Member] | Maximum [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life			12 years
AIQA Cedar Inc [Member]
Business Acquisition [Line Items]
Business Combination Cost Of Acquired Entity Purchase Price	30,415,000
Business Combination, Purchase Price Allocation Secured Loan Amount	15,500,000
Business Combination, Contigent Loan Amount	1,000,000
Merger Agreement, Potential Termination Fee	3,000,000
Merger Agreement, Potential Termination Fee from Acquiree	$4,000,000

Inventory_Details

Inventory (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Inventory [Line Items]
Raw materials	$220,378	$197,514
Work in process	546,419	489,431
Finished goods	835,546	725,897
Less: Inventory reserve	-616	-1,094
Total	$1,601,727	$1,411,748

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Gross Amount	$6,891,333	$6,891,333
Accumulated Amortization	-2,736,709	-2,504,040
Net Carrying Amount	4,154,624	4,387,293
Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	10 years	10 years
Gross Amount	5,396,000	5,396,000
Accumulated Amortization	-2,069,633	-1,934,733
Net Carrying Amount	3,326,367	3,461,267
Customer relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	776,000	776,000
Accumulated Amortization	-326,260	-308,871
Net Carrying Amount	449,740	467,129
Customer relationships [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	9 years	9 years
Customer relationships [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	12 years	12 years
Distribution rights [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	5 years 3 months 7 days	5 years 3 months 7 days
Gross Amount	400,000	400,000
Accumulated Amortization	-115,928	-96,880
Net Carrying Amount	284,072	303,120
Tradename [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	3 years	3 years
Gross Amount	111,000	111,000
Accumulated Amortization	-33,916	-24,667
Net Carrying Amount	77,084	86,333
Non-compete [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	1 year	1 year
Gross Amount	208,333	208,333
Accumulated Amortization	-190,972	-138,889
Net Carrying Amount	$17,361	$69,444

Intangible_Assets_Details_Text

Intangible Assets (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$232,669	$106,548
Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year	791,790
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	722,346
Finite-Lived Intangible Assets, Amortization Expense, Year Two	697,679
Finite-Lived Intangible Assets, Amortization Expense, Year Three	683,704
Finite-Lived Intangible Assets, Amortization Expense, Year Four	$334,156

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Accrued Liabilities Current Line Items [Line Items]
Salaries, benefits and incentive compensation	$1,495,878	$1,528,229
Professional fees	494,030	228,426
Royalty fees	173,016	100,537
Deferred revenue	78,000	78,523
Deferred lease incentive liability	8,337	8,337
Other	81,615	123,807
Total accrued expenses and other current liabilities	$2,330,876	$2,067,859

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (EUR €)	Mar. 31, 2015
Commitments And Contingencies [Line Items]
2015	€ 1,000,000
2016	2,500,000
2017	€ 4,000,000

Commitments_and_Contingencies_2

Commitments and Contingencies (Details Textual) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2011	Dec. 31, 2014
Commitments And Contingencies [Line Items]
Accrued Liabilities, Current	$2,330,876			$2,067,859
Accounts Payable, Current	1,802,498			1,757,742
Debt Instrument, Payment Terms	Debt Financing will (i) have a four year term, (ii) accrue interest at an annual rate equal to (a) the greater of one-month LIBOR or 1% plus (b) 9.75%, (iii) be interest only for the first 24 months, followed by monthly amortization payments of $225,000, with the remaining unpaid balance due on the maturity date and (iv) be secured by a first priority lien on substantially all of the Companys assets.
Warrants Issued During Period, Warrants, New Issues	750,000
Exit fee payment, Credit Agreement Description	The Company will also be required to pay an exit fee when the term loan is paid in full equal to the greater of 1% of the outstanding principal balance immediately prior to the final payment and $100,000.
AIQA Cedar Inc [Member]
Commitments And Contingencies [Line Items]
Accrued Liabilities, Current	123,781
Accounts Payable, Current	1,219
Business Combination, Purchase Price Allocation Secured Loan Amount	15,500,000
Alliqua Biomedical Subsidiary [Member]
Commitments And Contingencies [Line Items]
Contractual Obligation, Future Minimum Payments Due, Remainder of Fiscal Year	500,000
Contractual Obligation, Due in Next Twelve Months	600,000
Royalty Expense	125,000	100,000
Noble Fiber Technologies License Agreement [Member]
Commitments And Contingencies [Line Items]
Royalty Fee Percentage			9.75%
Sorbion Distributor Agreement [Member]
Commitments And Contingencies [Line Items]
Recorded Unconditional Purchase Obligation, Due in Next Rolling Twelve Months	1,085,010
Recorded Unconditional Purchase Obligation, Due in Rolling Year Two	2,712,530
Recorded Unconditional Purchase Obligation, Due in Rolling Year Three	$4,340,040

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	$1,940,912	$5,144,315
Share Based Compensation Plan [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	2,032,512	5,161,525
Share Based Compensation Plan [Member] | Options [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	1,530,541	3,464,956
Share Based Compensation Plan [Member] | Warrants [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	0	197,792
Share Based Compensation Plan [Member] | Restricted stock units [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	0	180,715
Share Based Compensation Plan [Member] | Restricted stock [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	$501,971	$1,318,062

Stockholders_Equity_Details_1

Stockholders' Equity (Details 1) (USD $)	3 Months Ended
	Mar. 31, 2015
Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date	6-Feb-15
Shares Issued	600,000
Vesting Term	[1]	[1]
Grant Date Value	$3,738,000
Restricted Stock Total [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Issued	600,000
Grant Date Value	$3,738,000
[1]	Vests in three equal annual installments, with one-third vesting on each of February 6, 2016, February 6, 2017 and February 6, 2018.

Stockholders_Equity_Details_2

Stockholders' Equity (Details 2) (Restricted Stock [Member], USD $)	3 Months Ended
	Mar. 31, 2015
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Non-vested, December 31, 2014 (in shares)	188,149
Number of Shares, Granted (in shares)	600,000
Number of Shares, Vested (in shares)	-46,174
Number of Shares, Forfeited (in shares)	0
Number of Shares, Non-vested, March 31, 2015 (in shares)	741,975
Weighted Average Grant Date Fair Value, Non-vested, December 31, 2014 (in dollars per share)	$7.03
Weighted Average Grant Date Fair Value, Granted (in dollars per share)	$6.23
Weighted Average Grant Date Fair Value, Vested (in dollars per share)	$6.99
Weighted Average Grant Date Fair Value, Forfeited (in dollars per share)	$0
Weighted Average Grant Date Fair Value, Non-vested, March 31, 2015 (in dollars per share)	$6.38
Total Grant Date Fair Value, Non-vested, December 31, 2014	$1,322,096
Total Grant Date Fair Value, Granted	3,738,000
Total Grant Date Fair Value, Vested	-322,756
Total Grant Date Fair Value, Forfeited	0
Total Grant Date Fair Value, Non-vested, March 31, 2015	$4,737,340

Stockholders_Equity_Details_3

Stockholders' Equity (Details 3) (Warrant [Member], USD $)	3 Months Ended
	Mar. 31, 2015
Warrant [Member]
Statement [Line Items]
Number of Options, Outstanding at Beginning of the period (in shares)	2,675,121
Number of Warrants, Issued (in shares)	0
Number of Warrants, Exercised (in shares)	0
Number of Warrants, Cancelled (in shares)	0
Number of Options, Outstanding at End of the period (in shares)	2,675,121
Number of Warrants, Exercisable, March 31, 2015 (in shares)	2,675,121
Weighted Average Exercise Price, Outstanding, Beginning of the period, (in dollars per share)	$5.76
Weighted Average Exercise Price, Issued (in dollars per share)	$0
Weighted Average Exercise Price, Exercised (in dollars per share)	$0
Weighted Average Exercise Price, Cancelled (in dollars per share)	$0
Weighted Average Exercise Price, Outstanding, End of the period, (in dollars per share)	$5.76
Weighted Average Exercise Price, Exercisable March 31, 2015 (in dollars per share)	$5.76
Weighted Average Remaining Life In Years, Outstanding, March 31, 2015 (Years)	3 years 4 months 24 days
Weighted Average Remaining Life In Years, Exercisable, March 31, 2015 (Years)	3 years 4 months 24 days
Intrinsic Value, Outstanding, March 31, 2015	$1,399,606
Intrinsic Value, Exercisable, March 31, 2015	$1,399,606

Stockholders_Equity_Details_4

Stockholders' Equity (Details 4) (Warrant [Member], USD $)	3 Months Ended
	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	2,675,121
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 4 months 24 days
Warrants Exercisable, Number of Warrants	2,675,121
Exercise Price Range, 2.19 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	2.19
Warrants Outstanding, Number of Warrants	108,572
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 6 months
Warrants Exercisable, Number of Warrants	108,572
Exercise Price Range, 3.02 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	3.02
Warrants Outstanding, Number of Warrants	74,286
Warrants Exercisable, Weighted Average Remaining Life In Years	1 year 10 months 24 days
Warrants Exercisable, Number of Warrants	74,286
Exercise Price Range, 3.50 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	3.5
Warrants Outstanding, Number of Warrants	2,286
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 1 month 6 days
Warrants Exercisable, Number of Warrants	2,286
Exercise Price Range, 4.24 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	4.24
Warrants Outstanding, Number of Warrants	780,191
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 2 months 12 days
Warrants Exercisable, Number of Warrants	780,191
Exercise Price Range, 4.38 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	4.38
Warrants Outstanding, Number of Warrants	188,444
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 7 months 6 days
Warrants Exercisable, Number of Warrants	188,444
Exercise Price Range, 4.81 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	4.81
Warrants Outstanding, Number of Warrants	8,889
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 7 months 6 days
Warrants Exercisable, Number of Warrants	8,889
Exercise Price Range, 5.69 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	5.69
Warrants Outstanding, Number of Warrants	1,040,880
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 7 months 6 days
Warrants Exercisable, Number of Warrants	1,040,880
Exercise Price Range, 7.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	7
Warrants Outstanding, Number of Warrants	18,286
Warrants Exercisable, Weighted Average Remaining Life In Years	1 month 6 days
Warrants Exercisable, Number of Warrants	18,286
Exercise Price Range, 8.75 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	8.75
Warrants Outstanding, Number of Warrants	25,429
Warrants Exercisable, Weighted Average Remaining Life In Years	3 months 18 days
Warrants Exercisable, Number of Warrants	25,429
Exercise Price Range, 10.50 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	10.5
Warrants Outstanding, Number of Warrants	427,858
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years
Warrants Exercisable, Number of Warrants	427,858

Stockholders_Equity_Details_5

Stockholders' Equity (Details 5) (Employee Stock Option [Member])	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.67%	1.90%
Expected term (years)	6 years	5 years 11 months 1 day
Expected volatility	98.25%	102.63%
Expected dividends	0.00%	0.00%

Stockholders_Equity_Details_6

Stockholders' Equity (Details 6) (Employee Stock Option [Member], USD $)	3 Months Ended
	Mar. 31, 2015
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Outstanding at Beginning of the period (in shares)	4,817,660
Number of Options, Granted (in shares)	795,500
Number of Options, Exercised (in shares)	-53,986
Number of Options, Forfeited (in shares)	-36,667
Number of Options, Outstanding at End of the period (in shares)	5,522,507
Number of Options, Exercisable, March 31, 2015 (in shares)	2,620,641
Weighted Average Exercise Price, Outstanding, Beginning of the period, (in dollars per share)	$6.56
Weighted Average Exercise Price, Granted (in dollars per share)	$6.17
Weighted Average Exercise Price, Exercised (in dollars per share)	$4.38
Weighted Average Exercise Price, Forfeited (in dollars per share)	$6.59
Weighted Average Exercise Price, Outstanding, End of the period, (in dollars per share)	$6.52
Weighted Average Exercise Price, Exercisable March 31, 2015 (in dollars per share)	$5.91
Weighted Average Remaining Life In Years, Outstanding, March 31, 2015 (Years)	8 years
Weighted Average Remaining Life In Years, Exercisable, Exercisable, March 31 2015 (Years)	6 years 10 months 24 days
Intrinsic Value, Outstanding, March 31, 2015	$1,603,929
Intrinsic Value, Exercisable, March 31, 2015	$1,395,540

Stockholders_Equity_Details_7

Stockholders' Equity (Details 7) (Employee Stock Option [Member], USD $)	3 Months Ended
	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Outstanding Number of Options (in shares)	5,522,507
Options Exercisable, Exercisable Number of Options (in shares)	2,620,641
Exercise Price Range 3.28 - 3.99 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$3.28
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	$3.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$3.40
Options Outstanding, Outstanding Number of Options (in shares)	433,971
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$3.36
Options Exercisable, Weighted Average Remaining Life in Years (in years)	8 years 1 month 6 days
Options Exercisable, Exercisable Number of Options (in shares)	403,971
Exercise Price Range 4.00 - 4.99 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$4
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	$4.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$4.42
Options Outstanding, Outstanding Number of Options (in shares)	1,038,415
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$4.38
Options Exercisable, Weighted Average Remaining Life in Years (in years)	4 years 1 month 6 days
Options Exercisable, Exercisable Number of Options (in shares)	792,704
Exercise Price Range 5.00 - 5.99 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$5
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	$5.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$5.40
Options Outstanding, Outstanding Number of Options (in shares)	355,427
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$5.52
Options Exercisable, Weighted Average Remaining Life in Years (in years)	6 years 10 months 24 days
Options Exercisable, Exercisable Number of Options (in shares)	127,960
Exercise Price Range 6.00 - 6.99 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$6
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	$6.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$6.59
Options Outstanding, Outstanding Number of Options (in shares)	2,277,677
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$6.76
Options Exercisable, Weighted Average Remaining Life in Years (in years)	8 years 6 months
Options Exercisable, Exercisable Number of Options (in shares)	750,608
Exercise Price Range 7.00 - 7.99 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$7
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	$7.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$7.75
Options Outstanding, Outstanding Number of Options (in shares)	31,000
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$0
Options Exercisable, Weighted Average Remaining Life in Years (in years)	0 years
Options Exercisable, Exercisable Number of Options (in shares)	0
Exercise Price Range 8.00 - 8.99 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$8
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	$8.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$8.74
Options Outstanding, Outstanding Number of Options (in shares)	800,898
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$8.75
Options Exercisable, Weighted Average Remaining Life in Years (in years)	7 years 9 months 18 days
Options Exercisable, Exercisable Number of Options (in shares)	390,293
Exercise Price Range 9.00 - 9.99 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$9
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	$9.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$9.01
Options Outstanding, Outstanding Number of Options (in shares)	321,500
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$9
Options Exercisable, Weighted Average Remaining Life in Years (in years)	8 years 10 months 24 days
Options Exercisable, Exercisable Number of Options (in shares)	117,161
Exercise Price Range 10.00 - 26.69 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$10
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	$26.69
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$10.96
Options Outstanding, Outstanding Number of Options (in shares)	263,619
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$11.05
Options Exercisable, Weighted Average Remaining Life in Years (in years)	7 years 10 months 24 days
Options Exercisable, Exercisable Number of Options (in shares)	37,944

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)	0 Months Ended	3 Months Ended
	Jan. 06, 2014	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense		1,940,912	$5,144,315
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total		7,403,090
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		1 year 8 months 12 days
Stock Issued During Period Shares Warrants Exercised		53,986
Number Of Warrants To Purchase Common Stock Exercised		53,986
Warrants Exercised, Intrinsic Value		67,156
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		795,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		3,834,816
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		4.82	$6.58
Employee Stock Option [Member] | Excisable in Cash [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from Warrant Exercises		236,278
Employee Stock Option One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		791,000
Employee Stock Option Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		4,500
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense		91,600	17,210
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense		1,940,912	5,144,315
Plan 2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		1,828,571
Allocated Share-based Compensation Expense			98,915
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	194,667	62,777
Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		371,000
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Forfeiture Rate		0.00%
Minimum [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		5.01
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Forfeiture Rate		5.00%
Maximum [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		6.23
4.38 Exercise Price [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Investment Warrants, Exercise Price		4.38
Non Employee Director [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total		74,524
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total		3,563,477
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		1 year 9 months 18 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		600,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		6.23
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants To Purchase Common Stock		75,429
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		0
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		0
Investment Warrants, Exercise Price		2.19

Related_Party_Details_Textual

Related Party (Details Textual) (USD $)	0 Months Ended	3 Months Ended
	Jan. 06, 2014	Mar. 31, 2015	Mar. 31, 2014
Related Party Transaction [Line Items]
Allocated Share-based Compensation Expense		1,940,912	$5,144,315
Plan 2011 [Member]
Related Party Transaction [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	194,667	62,777
Allocated Share-based Compensation Expense			$98,915
Option Cancellation and Release Agreement [Member]
Related Party Transaction [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	278,096
Option Cancellation and Release Agreement [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	6.34
Option Cancellation and Release Agreement [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	9.19

Concentration_of_Risk_Details

Concentration of Risk (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Sales Revenue, Net [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	26.00%	55.00%
Sales Revenue, Net [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	0.00%	11.00%
Accounts Receivable [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	23.00%
Accounts Receivable [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	0.00%

Fair_Value_Measurement_Details

Fair Value Measurement (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$304,223	$933,465
Change in fair value of warrant liability	-12,042	283,267
Value of warrants exercised	0	-672,632
Ending balance	292,181	544,100
Contingent Consideration [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	2,931,598
Change in fair value of warrant liability	107,536
Ending balance	$3,039,134

Fair_Value_Measurement_Details1

Fair Value Measurement (Details 1) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
Liabilities:
Warrant liabilities	$292,181	$304,223	$544,100	$933,465
Fair Value, Inputs, Level 1 [Member]
Liabilities:
Warrant liabilities	0	0
Contingent consideration	0	0
Total liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Liabilities:
Warrant liabilities	0	0
Contingent consideration	0	0
Total liabilities	0	0
Fair Value, Inputs, Level 3 [Member]
Liabilities:
Warrant liabilities	292,181	304,223
Contingent consideration	3,039,134	2,931,598
Total liabilities	$3,331,315	$3,235,821

Fair_Value_Measurement_Details2

Fair Value Measurement (Details Textual) (Fair Value, Inputs, Level 3 [Member], USD $)	0 Months Ended
	Mar. 31, 2015
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Expected Volatility Rate	98.25%
Fair Value Assumptions, Risk Free Interest Rate	0.89%
Fair Value Assumptions, Expected Term	2 years 7 months 10 days
Fair Value Assumptions, Expected Dividend Rate	0.00%
Warrants To Purchase Common Stock	75,429
Fair Value, Liabilities Measured on Recurring Basis, Change in Unrealized Gain (Loss)	$12,042

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (Subsequent Event [Member], USD $)	0 Months Ended	1 Months Ended
	4-May-15	31-May-15
Subsequent Event [Member]
Subsequent Event [Line Items]
Shares Issued, Price Per Share	$4.55
Proceeds From Issuance Or Sale Of Equity Net of Underwriter fee		$32,430,000
Stock Issued During Period, Shares, New Issues	7,582,418